Form 4: Serina Therapeutics Director Steven Mintz Acquires Stock Options
SEC Form 4 Filing
Director Steven Mintz reports acquisition of stock options in Serina Therapeutics.
Summary
- On April 1, 2024, Steven Mintz, a director of Serina Therapeutics, Inc., acquired 40,000 stock options.
- The options have an exercise price of $11.828.
- The options vest in three equal installments on April 1, 2025, April 1, 2026, and April 1, 2027, contingent upon continued service.
- Mintz's holdings of derivative securities after the transaction is 41,812.
- The filing also notes a 1-for-35.17 reverse stock split of Serina Therapeutics' common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the actions of company directors.
Key Dates
| Date | Description |
|---|---|
| 04/01/2024 | Date of stock option acquisition and grant. |
| 04/01/2025 | First vesting date for the stock options. |
| 04/01/2026 | Second vesting date for the stock options. |
| 04/01/2027 | Third vesting date for the stock options. |
| 04/03/2024 | Date of Form 4 filing. |
| 04/01/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.